We here at CGD tend to be critical of international agencies like WHO or the UNDP for establishing targets or guidelines without sufficient consideration of the impacts, for good and ill, of those guidelines in the affected countries. Such guidelines often apply standards more appropriate to rich countries and then pressure poor countries to behave as if they were rich.
CGD Policy Blogs
This is a joint post with Rachel Silverman.
Through our Value for Money working group, we’ve spent much of the past year immersed in the world of global health funding agencies. With so many new agencies, particularly in the last quarter century (Figure 1), understanding the intricacies of the global health family can be daunting, even for the most devoted observers.
UNAIDS, WHO, PEPFAR and the Global Fund for AIDS TB and Malaria (GFATM) all depend on long-run projections in order to make the case for increased attention and financing for AIDS. This dependency is a response to the reality that HIV is a slow epidemic with extraordinary “momentum”. Even small changes in the course of new infections require years to implement and have health and fiscal consequences for decades thereafter. According to the UNAIDS web site, “[s]ince 2001, the UNAIDS Secretariat have le
Here in Vienna, at the crossroads of Europe, 20,000 people from 185 countries have gathered for the 18th International AIDS Conference. The Austrian physician who chairs the conference, Dr.
The global health community is an ambitious group; we often gravitate to the "big ideas" that revolutionize the way that things are done. But sometimes you don't need to change the rules to make a difference - you only need to apply them creatively.
Victoria Hale, head of OneWorld Health, an innovative non-profit pharmaceutical firm, reckons that compulsory licensing could prove "the last blow" that pushes the drug industry away from looking for cures for diseases of the poor world, which are already woefully neglected...
Bruce Lehman, a lawyer who worked on the TRIPS [sic] accord in the Clinton administration, thinks it is cynical for middle-income countries "to avoid paying their fair share of drug-discovery costs."
Once again, volatile demand for flu vaccine is giving everyone a headache. A mere two years ago supply fell badly short of demand, turning US seniors into "immunization tourists" to Canada, and putting President Bush on the defensive during the 2004 campaign. This year, demand is way off, and suppliers can barely give the vaccine away; they face the prospect of wasting valuable doses because the vaccine is developed specifically for this year's strain.
In the midst of all the recent political developments in global health, there's an exciting surprise on the scientific front: a new study in the New England Journal of Medicine has found that chloroquine cured 99% of malaria cases in a study of 105 children in Malawi, over 12 years after it was withdrawn due to treatment failure rates of over 50% (as reported in the Seattle Post-Intelligencer and elsewhere).